Key Takeaways
  • No major US guideline tells every man to get a PSA test. They disagree on when to start the conversation: 40, 45, 50 or 55, depending on the guideline and your risk
  • The benefit is real but modest. In the European ERSPC trial, screening cut prostate cancer deaths by 13% over 23 years: one death prevented per 456 men invited
  • The main harm is overdiagnosis: finding slow cancers that would never have caused harm, in an estimated 20% to 50% of screen-detected cases, says the USPSTF
  • Black men, men with a father or brother diagnosed young, and BRCA2 carriers are at higher risk and may start earlier
  • Screening is gentler than it was. MRI can now come before biopsy, and in one US registry, monitoring instead of treating low-risk cancer rose from 26.5% in 2014 to 59.6% in 2021

Our guide to blood tests after 40 promised PSA its own article. It's the routine-looking blood test where experts genuinely disagree, and the right answer depends on your age, your family and how you weigh the trade-offs.

Here's what the big trials found, what each guideline says for your age, and what to ask. It's an evidence summary, not medical advice: make the decision with your own doctor.

13%
Reduction in prostate cancer deaths among men invited to PSA screening, after a median 23 years of follow-up in the ERSPC trial of 162,236 men aged 55 to 69 in eight European countries (New England Journal of Medicine, 2025)
Part one · The test

What PSA Is, and Why It's Contested

Prostate-specific antigen (PSA) is a protein made by both normal and cancerous prostate cells, measured in a blood test. Generally a level above 4.0 ng/mL is considered abnormal, though some doctors use higher cut-offs for older men and lower ones for younger men (National Cancer Institute).

But PSA isn't specific to cancer. An enlarged prostate and inflammation raise it too, and only about 25% of men who have a biopsy because of a raised PSA are found to have prostate cancer (NCI). The US Preventive Services Task Force (USPSTF) lists the trade-offs plainly (USPSTF, 2018):

That's the debate in miniature: a few men avoid dying of prostate cancer, while more are diagnosed with, and sometimes treated for, cancers that were never going to hurt them.

Part two · The evidence

What the Big Trials Found

Evidence: Strong — three large randomised trials, mixed results

ERSPC: a lasting benefit in Europe

The European Randomized Study of Screening for Prostate Cancer (ERSPC) randomly assigned 162,236 men aged 55 to 69 in eight countries between 1993 and 2003. 72,888 were offered PSA screening, typically every 4 years; 89,348 weren't invited. The 23-year results appeared in the New England Journal of Medicine in October 2025 (Roobol, NEJM 2025; ASCO Post).

The authors concluded that future screening "should adopt risk-based approaches to minimize overdiagnosis while maintaining clinical benefits." Anssi Auvinen of Tampere University, one of the principal investigators, added: "the effect starts to wane once screening is discontinued and largely disappears within nine years" (Tampere University).

Figure 1 · ERSPC, 16 vs 23 years

The cost of preventing one death has fallen with time

Men invited per death prevented 16 years 628 23 years 456 Men diagnosed per death prevented 16 years 18 23 years 12 Lower is better. Each panel has its own scale.

Roobol et al., NEJM 2025 (abstract). "Diagnosed" counts men diagnosed with prostate cancer for each death prevented.

PLCO: no difference, but a contaminated comparison

The US PLCO (Prostate, Lung, Colorectal and Ovarian) trial randomised 76,683 men aged 55 to 74 between 1993 and 2001. The screening group got yearly PSA tests for 6 years and rectal exams for 4. After a median of about 15 years, there were 255 prostate cancer deaths in the screening group and 244 in the control group (rate ratio 1.04; 95% CI 0.87 to 1.24), so no reduction (Pinsky, Cancer 2017).

The catch: an estimated 86% of control-group men had a PSA test anyway, against 99% in the screening group. The authors wrote that the result "can be viewed as showing no benefit of organized screening versus opportunistic screening" (Pinsky, Cancer 2017), which is not the same as showing PSA testing doesn't work.

CAP: one test, a small effect

The UK CAP trial asked what a single PSA test does. It included 415,357 men aged 50 to 69 registered with GP practices in England and Wales. Practices were randomised, and men in the intervention group got one invitation for a PSA test, with a biopsy offered if PSA was 3.0 ng/mL or more. Only 40% of invited men had a test (Martin, JAMA 2024).

After a median of 15 years, 0.69% of the invited group had died of prostate cancer against 0.78% of the control group (rate ratio 0.92; 95% CI 0.85 to 0.99), a difference of 0.09 percentage points. More low-grade cancers were found (Gleason 6 or lower: 2.2% vs 1.6%), and deaths from all causes didn't differ. The authors called the absolute reduction in deaths "small", and the University of Bristol estimated that one in six cancers found by the single test were overdiagnosed (University of Bristol).

Figure 2 · The three big trials

What each trial tested, and what it found

TrialWho and whatProstate cancer deathsThe catch
ERSPC 8 European countries162,236 men aged 55–69; PSA usually every 4 years13% lower at 23 years RR 0.87 (0.80–0.95); 1 death prevented per 456 invited12 men diagnosed per death prevented; benefit wanes after screening stops
PLCO United States76,683 men aged 55–74; yearly PSA for 6 yearsNo difference at about 15 years RR 1.04 (0.87–1.24)86% of the control group had a PSA test anyway
CAP England and Wales415,357 men aged 50–69; one PSA test invitation0.69% vs 0.78% at 15 years RR 0.92 (0.85–0.99)Only 40% of invited men were tested; more low-grade cancers found

Roobol, NEJM 2025; Pinsky, Cancer 2017; Martin, JAMA 2024. RR = rate ratio (95% confidence interval).

Part three · The guidelines

The Guidelines, Age by Age

Together, the trials say screening can cut prostate cancer deaths by a small absolute amount, at the cost of extra diagnoses. Guideline bodies weigh that differently.

USPSTF (2018): an individual decision from 55 to 69

For men aged 55 to 69, the USPSTF says the decision to have periodic PSA screening "should be an individual one" (grade C). It recommends against PSA screening in men 70 and older (grade D). It made no separate recommendation for Black men or men with a family history, though it named both as major risk factors, alongside age (USPSTF).

The Task Force's page says the topic "is being updated". It posted a final research plan on 21 December 2023 (USPSTF), but as of mid-October 2026 we found no new draft recommendation on its site. The 2018 statement still stands.

American Cancer Society: talk about it at 50, 45 or 40

The ACS recommends that men "have a chance to make an informed decision with their health care provider" about screening, starting (ACS, revised November 2023):

With a PSA below 2.5 ng/mL, retesting every 2 years may be enough; at 2.5 or higher, yearly. Men without symptoms and with less than a 10-year life expectancy shouldn't be offered screening.

AUA/SUO (2023): a baseline PSA in your late 40s

The urologists' guideline (American Urological Association and Society of Urologic Oncology) is the most proactive (AUA/SUO, 2023):

The UK: targeted screening for BRCA2 carriers

The UK has no screening programme for all men, but men can ask their GP for a PSA test after discussing the pros and cons. In May 2026 the UK National Screening Committee recommended a PSA test every two years for men aged 45 to 61 with a confirmed BRCA2 gene change and a relevant family history. It advised against screening all men, Black men, or men with a family history but no BRCA2 change. As Cancer Research UK puts it, "the PSA blood test is not a reliable enough test to screen all men." The UK government accepted the recommendation for England in June 2026, with screening expected to roll out in 2027; Scotland, Wales and Northern Ireland are still considering it (DHSC; UK NSC; Cancer Research UK).

Figure 3 · Side by side

What each guideline says at your age

AgeUSPSTF (2018)American Cancer SocietyAUA/SUO (2023)UK
40–44Not coveredDiscuss at 40 if more than one close relative diagnosed earlyOffer screening from 40–45 if higher riskNo national screening; can ask GP
45–49Not coveredDiscuss at 45 if Black, or father/brother diagnosed before 65May offer a baseline PSA (45–50)From 2027 (England): PSA every 2 years, ages 45–61, for BRCA2 carriers with a family history otherwise no national screening; can ask GP
50–54Not coveredDiscuss at 50 if average risk and expected to live 10+ yearsOffer screening every 2–4 yearsBRCA2 programme continues to 61 otherwise no national screening; can ask GP
55–69Individual decision grade CIf screening: retest every 2 years if PSA under 2.5; yearly if 2.5+Offer screening every 2–4 years to age 69BRCA2 programme to 61 otherwise no national screening; can ask GP
70+Recommends against grade DNot offered if life expectancy under 10 yearsPersonalise or stop, by age, PSA and healthNo national screening; can ask GP

USPSTF 2018; ACS (revised November 2023); AUA/SUO Early Detection of Prostate Cancer guideline, 2023; UK National Screening Committee (May 2026); Department of Health and Social Care (June 2026).

Part four · Higher risk

Who Should Start the Conversation Earlier

About 1 in 8 US men will be diagnosed with prostate cancer during their lifetime, and about 1 in 49 will die of it. The ACS estimates 333,830 new US cases and 36,320 deaths in 2026; the average age at diagnosis is about 68 (ACS). Three groups carry more risk:

Part five · What's changed

Why a Raised PSA Is Less Fraught Than It Was

Much of the case against screening came from what followed a raised PSA: biopsies, and treatment for cancers that might never have caused harm. Two changes have softened that.

MRI before biopsy. The AUA/SUO guideline says clinicians may use MRI before a first biopsy to better detect clinically significant cancers, and should get one before a repeat biopsy if there hasn't been one (AUA/SUO). A suspicious area on MRI can then be biopsied directly (NCI).

Active surveillance. This means monitoring a low-risk cancer instead of treating it straight away; the USPSTF describes it as an approach that "seeks to limit the harms of treatment". In the AUA's AQUA registry of 20,809 men with low-risk disease at 349 US practices, its use rose from 26.5% in 2014 to 59.6% in 2021 (Cooperberg, JAMA Netw Open 2023, via The ASCO Post).

Part six · What to do

Before and After the Test

Things that can raise PSA temporarily

According to the National Cancer Institute (NCI):

Ask your doctor or lab whether you should avoid sex or a long ride in the days before the test.

What a "high" result usually means next

A single raised PSA isn't a diagnosis. The NCI says a doctor may repeat the test in 6 to 8 weeks, and the AUA/SUO guideline says to repeat a newly raised PSA before imaging or biopsy. If it stays high, options include more PSA tests, a rectal exam, an MRI and, if needed, a biopsy.

Questions to ask your doctor

Frequently Asked Questions

At what age should men start PSA screening?
It depends on the guideline and your risk. The American Cancer Society says to discuss it at 50, at 45 for Black men and men whose father or brother was diagnosed before 65, or at 40 for men with more than one close relative diagnosed young. The AUA/SUO guideline allows a baseline PSA at 45 to 50. The USPSTF calls screening at 55 to 69 an individual decision.
Should men over 70 get a PSA test?
The USPSTF recommends against PSA screening from 70 (grade D). The American Cancer Society says men expected to live less than 10 more years shouldn't be offered it, and the AUA/SUO guideline says screening can be stopped based on age, health and past PSA results. Talk it through with your doctor.
Does PSA screening save lives?
Modestly. In the European ERSPC trial of 162,236 men, screening cut prostate cancer deaths by 13% over 23 years, one death prevented per 456 men invited. In the UK CAP trial, one PSA test invitation lowered prostate cancer deaths from 0.78% to 0.69% over 15 years.
What happens if my PSA is high?
Usually a repeat test first: the National Cancer Institute says a doctor may repeat it in 6 to 8 weeks. If it stays high, next steps can include an MRI and, if needed, a biopsy. Only about 25% of men biopsied for a raised PSA have cancer.
What can raise PSA besides prostate cancer?
According to the National Cancer Institute: an enlarged prostate (BPH), prostatitis, vigorous exercise such as cycling, ejaculation, and a prostate biopsy in the past month or two. Finasteride and dutasteride lower PSA, so tell your doctor if you take them.
The Bottom Line

A real benefit, a real trade-off, and your call.

PSA screening prevents a small number of prostate cancer deaths, and the benefit in the longest trial has grown with time. The price is extra diagnoses, though MRI and active surveillance now soften what follows a raised result.

In your 40s, learn your family history and ask your doctor when to start, especially if you're Black, carry a BRCA2 change or had a father or brother diagnosed young. From 55 to 69, all three US guidelines support an informed choice. Past 70, the case weakens. Decide with your doctor, not by default.

Sources

  1. Roobol MJ, de Vos II, Månsson M, et al. European Study of Prostate Cancer Screening — 23-Year Follow-up. New England Journal of Medicine 2025;393(17):1669–1680 (doi:10.1056/NEJMoa2503223). As reported by The ASCO Post (November 2025).
  2. Tampere University. Study confirms sustained reduction in prostate cancer mortality with PSA screening. 3 November 2025.
  3. Pinsky PF, Prorok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 2017;123(4):592–599 (doi:10.1002/cncr.30474).
  4. Martin RM, Turner EL, Young GJ, et al. Prostate-specific antigen screening and 15-year prostate cancer mortality: a secondary analysis of the CAP randomized clinical trial. JAMA 2024;331(17):1460, published online 6 April 2024 (doi:10.1001/jama.2024.4011).
  5. University of Bristol. Screening with a PSA test has a small impact on prostate cancer deaths but leads to overdiagnosis. April 2024.
  6. US Preventive Services Task Force. Prostate Cancer: Screening. Final recommendation, 8 May 2018 (update in progress).
  7. US Preventive Services Task Force. Final Research Plan: Screening for Prostate Cancer. 21 December 2023.
  8. American Cancer Society. American Cancer Society Recommendations for Prostate Cancer Early Detection. Revised 22 November 2023.
  9. American Cancer Society. Key Statistics for Prostate Cancer (2026 estimates) and Prostate Cancer Risk Factors.
  10. American Cancer Society. New ACS prostate cancer statistics report. 2 September 2025 (report in CA: A Cancer Journal for Clinicians).
  11. American Urological Association and Society of Urologic Oncology. Early Detection of Prostate Cancer: AUA/SUO Guideline (2023). Part I: prostate cancer screening. Wei JT, Barocas D, Carlsson S, et al. Journal of Urology 2023;210(1):46–53 (doi:10.1097/JU.0000000000003491).
  12. National Cancer Institute. Prostate-Specific Antigen (PSA) Test.
  13. National Cancer Institute. BRCA Gene Changes: Cancer Risk and Genetic Testing.
  14. Cooperberg MR, Meeks W, Fang R, et al. Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US. JAMA Network Open 2023;6(3):e231439 (doi:10.1001/jamanetworkopen.2023.1439). Also reported by The ASCO Post (March 2023).
  15. UK National Screening Committee. UK NSC opens consultation on draft prostate cancer screening recommendation. 28 November 2025.
  16. UK National Screening Committee. Minutes published of UK NSC March 2026 meeting. 28 May 2026.
  17. Department of Health and Social Care. Major expansion of research and treatment for prostate cancer. 2 June 2026.
  18. Cancer Research UK. UK NSC recommends targeted prostate cancer screening. 28 May 2026; and Screening for prostate cancer.